Every material Form 8-K ALX ONCOLOGY HOLDINGS INC has filed with the SEC since June 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 14, 2026, ALX Oncology entered into exchange agreements under which certain stockholders surrendered 13,353,384 shares of common stock to the company in return for pre-funded warrants to buy the same number of shares. The exchange is expected to settle on or about October 15, 2026, and the filing does not state any cash proceeds to the company, so the change affects the form of the holdings rather than the company's cash position as described.
Stockholders surrendered 13,353,384 common shares in exchange for pre-funded warrants for the same number of shares.
Blackstone Annex Master Fund L.P. affiliates accounted for 12,885,891 shares; RA Capital Healthcare Fund, L.P. for 213,667 shares; venBio Global Strategic Fund, L.P. for 253,826 shares.
Pre-funded warrants have an exercise price of $0.001 per share and are exercisable at any time, subject to 4.99% or 9.99% beneficial ownership limits.
ALX Oncology reported a second-quarter 2026 GAAP net loss of $18.0 million, or $0.13 per share, down from $25.9 million, or $0.49 per share, a year earlier. The company said cash, cash equivalents and investments were $153.4 million at June 30, 2026, and that this is sufficient to fund planned operations through the first half of 2028. Shareholders also face a larger share count, with weighted-average shares rising to about 135.6 million from 53.4 million.
Q2 2026 GAAP net loss was $18.0 million ($0.13 per share), versus $25.9 million ($0.49 per share) in Q2 2025; the prior-year period included a $3.2 million lease impairment charge.
R&D expenses fell to $13.1 million from $18.0 million; G&A expenses were $5.1 million versus $5.5 million.
Cash, cash equivalents and investments were $153.4 million at June 30, 2026, up from $48.3 million at December 31, 2025.
In June 2026, the company refinanced its $10 million debt with HSBC Ventures USA Inc., with a facility of up to $50 million, of which $10 million is uncommitted.
ALX Oncology said Chairman Corey Goodman, Ph.D. resigned from the board effective June 29, 2026, for personal reasons and not over any disagreement with the company. The board named independent director Scott Garland as chairman and reset committee memberships, and the company also appointed Michael Listgarten as General Counsel. The filing reports no financial results, so the change is a governance update rather than a change in operating performance.
Corey Goodman, Ph.D. resigned as chairman and as a director, effective close of business June 29, 2026
Scott Garland, an independent director since November 2022, became chairman effective June 29, 2026
Garland joins the Audit Committee; Chris Takimoto, M.D., Ph.D., chairs the Compensation Committee
Michael Listgarten was appointed General Counsel, effective immediately, per the June 30, 2026 press release
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ALX ONCOLOGY HOLDINGS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →